Article
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2011
Oxnard Geoffrey R, Arcila Maria E, Sima Camelia S, Riely Gregory J, Chmielecki Juliann, Kris Mark G, Pao William, Ladanyi Marc, Miller Vincent A
Abstract excerpt
PURPOSE: Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after a median of 10 to 16 months. In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.